CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Revenue increased 11.4 per cent to Rs. 8,545 crore
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Stable profits, low leverage to keep credit profiles comfortable
Subscribe To Our Newsletter & Stay Updated
